SIO Petitions NCCN to Expand Cryoablation Guidelines for Breast Cancer
Event summary
- The SIO petitioned the NCCN to include cryoablation as a Category 2B option for low-risk, early-stage breast cancer patients aged 50-69 who are poor surgical candidates or decline surgery.
- The petition cites IceCure's FDA clearance of ProSense® in October 2025 for treating biologically low-risk breast cancer in women aged 70+ with tumors ≤1.5 cm.
- The SIO also recommends considering cryoablation combined with whole-breast radiation and endocrine therapy for patients aged 50-69.
- The petition follows the March 2026 ASBrS resource guide update supporting cryoablation for appropriately selected low-risk, early-stage breast cancer patients.
The big picture
The SIO's petition to the NCCN marks a strategic push to broaden the use of minimally invasive cryoablation in breast cancer treatment. This aligns with broader industry trends toward less invasive, patient-friendly oncology solutions. IceCure's FDA clearance for ProSense® serves as a catalyst, potentially setting a precedent for other interventional oncology technologies seeking guideline recognition.
What we're watching
- Guideline Adoption
- How NCCN's potential inclusion of cryoablation will impact clinical awareness and adoption rates.
- Reimbursement Dynamics
- Whether guideline recognition will influence reimbursement discussions for cryoablation procedures.
- Patient Population Expansion
- The pace at which the eligible patient population for cryoablation may expand beyond current age and risk criteria.
Related topics